Compare EXPO & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXPO | BEAM |
|---|---|---|
| Founded | 1967 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.0B |
| IPO Year | 1996 | 2019 |
| Metric | EXPO | BEAM |
|---|---|---|
| Price | $61.44 | $25.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $88.00 | $50.75 |
| AVG Volume (30 Days) | 524.3K | ★ 2.6M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.87% | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $582,014,000.00 | $24,000.00 |
| Revenue This Year | $12.75 | N/A |
| Revenue Next Year | $8.50 | $33.77 |
| P/E Ratio | $101.66 | ★ N/A |
| Revenue Growth | 4.21 | ★ 33.33 |
| 52 Week Low | $51.91 | $15.60 |
| 52 Week High | $81.95 | $38.26 |
| Indicator | EXPO | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 53.12 | 30.23 |
| Support Level | $54.15 | $24.80 |
| Resistance Level | $69.49 | $33.32 |
| Average True Range (ATR) | 1.94 | 1.99 |
| MACD | -0.20 | -0.94 |
| Stochastic Oscillator | 37.89 | 1.83 |
Exponent Inc is a science and engineering consulting firm that provides solutions to complex problems. The company's consultant team is composed of scientists, physicians, engineers, as well as business and regulatory consultants. The company currently operates through two segments. The engineering and other scientific segments, which account for the majority of revenue, provide servicing encompassing biomechanics, biomedical engineering, buildings and structures, civil engineering, construction consulting, etc. The environmental and health segment covers chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences and others. The company generates almost all of its revenues from America.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.